---
title: "Actuate Therapeutics (ACTU) news: going concern and offering"
url: "https://aibio.space/companies/actuate-therapeutics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "ACTU going concern and offering news: Actuate Therapeutics presentation repeats going-concern doubt and need for capital. Actuate Therapeutics, Inc."
---

ACTU Actuate Therapeutics, Inc. NASDAQ · United States

# Actuate Therapeutics (ACTU) news ACTU going concern and offering news

Financings · 2026-10-28

## [Actuate Therapeutics prices $11.0 million offering of shares and warrants](https://aibio.space/news/actuate-therapeutics-prices-11-0-million-offering-shares-warrants/)

Actuate Therapeutics priced 30,985,900 shares and warrants for 15,492,950 more shares at $0.71 per set, for about $11.0 million before costs. The stock last sold at $0.40, and the company reported $4.4 million of cash at June 30, 2026.

## Latest Actuate Therapeutics news

1. 2025-09-09 Financings [Actuate Therapeutics prices 2,142,858 shares at $7.00 for $15,000,006 in gross proceeds](https://aibio.space/news/actuate-therapeutics-prices-2-142-858-shares-7-00-15-000-006-gross/) Actuate Therapeutics priced 2,142,858 shares at $7.00 for $15,000,006 in gross proceeds, below the $8.24 last sale price. Lucid Capital Markets is the sole underwriter, and the prospectus says the company's current liabilities exceeded its assets at June 30, 2025.
2. 2025-06-26 Financings [Actuate Therapeutics agrees to sell 666,497 shares at $7.00 in private placement](https://aibio.space/news/actuate-therapeutics-agrees-sell-666-497-shares-7-00-private-placement/) The deal pairs each share with a $7.00 warrant and is expected to bring in approximately $4.7 million in gross proceeds. Bios 2024 Co-Invest, LP, a current stockholder, is among the purchasers, and the filing says Bios would be deemed to own about 49.9% of the company.
3. 2025-06-02 Distress [Actuate Therapeutics presentation repeats going-concern doubt and need for capital](https://aibio.space/news/actuate-therapeutics-presentation-repeats-going-concern-doubt-need/) Actuate Therapeutics filed a corporate overview dated May 31, 2025 that repeats its going-concern warning and says it needs capital to fund operations beyond the second quarter of fiscal 2025. The deck's survival figures are draft, unaudited data, and its progression-free survival result is not statistically significant.

## Actuate Therapeutics at a glance

- **Ticker**: ACTU

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $4.4 million

### Related companies

- [Alumis](https://aibio.space/companies/alumis/) NASDAQ: ALMS
- [Savara](https://aibio.space/companies/savara/) NASDAQ: SVRA
- [aTyr Pharma](https://aibio.space/companies/atyr-pharma/) NASDAQ: ATYR
- [Electra Therapeutics](https://aibio.space/companies/electra-therapeutics/) NASDAQ: ETRA
- [Exelixis](https://aibio.space/companies/exelixis/) NASDAQ: EXEL
- [Pfizer](https://aibio.space/companies/pfizer-pfe/) NYSE: PFE
- [Erasca](https://aibio.space/companies/erasca/) NASDAQ: ERAS
- [Merck & Company](https://aibio.space/companies/merck-mrk-nyse/) NYSE: MRK

### Also on NASDAQ

- [Kiniksa Pharmaceuticals International](https://aibio.space/companies/kiniksa-pharmaceuticals-international/) KNSA
- [SAB Biotherapeutics](https://aibio.space/companies/sab-biotherapeutics/) SABS
- [iBio](https://aibio.space/companies/ibio/) IBIO
- [Xilio Therapeutics](https://aibio.space/companies/xilio-therapeutics/) XLO
- [Bio Green Med Solution](https://aibio.space/companies/bio-green-med-solution/) BGMS
- [Pulmatrix](https://aibio.space/companies/pulmatrix/) PULM

## What Actuate Therapeutics does

Actuate Therapeutics is a clinical-stage biopharmaceutical company developing therapies for high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). Its lead asset is elraglusib, an ATP-competitive small molecule that the company says blocks GSK-3β, a master regulator of signaling pathways that lead to tumor cell survival, growth, migration and invasion. The company has exclusively licensed elraglusib from a collaboration between the University of Illinois-Chicago and Northwestern University. Its most advanced indication is first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). A randomized, controlled Phase 2 trial in that setting, Actuate-1801 Part 3B, enrolled 286 patients, and data presented at ASCO GI in January 2026 showed that the trial met its primary endpoint of median overall survival. The company is also developing elraglusib in pediatric cancers, where it identified Ewing sarcoma and neuroblastoma as new indications. It has selected an oral tablet formulation for further development and plans a Phase 1 study, subject to future funding. Elraglusib holds orphan drug designations for pancreatic and other cancer types and fast track designation for pancreatic cancer.

| Product or program | What it is | Stage |
|---|---|---|
| Elraglusib Injection (mPDAC) | GSK-3β inhibitor given with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer | Phase 2 trial met primary endpoint |
| Elraglusib Injection (pediatric) | Intravenous GSK-3β inhibitor for recurrent or refractory pediatric solid cancers | Phase 1/2 (Actuate-1902) |
| Elraglusib Oral Tablet | Oral dosage form for advanced, refractory cancers | Phase 1 planned, subject to future funding |

Summarised from the company's [10-K filed Mar 26, 2026](https://www.sec.gov/Archives/edgar/data/1652935/000168316826002257/actuate_i10k-123125.htm).

## Actuate Therapeutics annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$10.3 million](https://www.sec.gov/Archives/edgar/data/1652935/000168316826002257/) | [$18.7 million](https://www.sec.gov/Archives/edgar/data/1652935/000168316826002257/) |
| Net income (loss) | [-$22.2 million](https://www.sec.gov/Archives/edgar/data/1652935/000168316826002257/) | [-$27.3 million](https://www.sec.gov/Archives/edgar/data/1652935/000168316826002257/) |
| Cash from operations | [-$19.2 million](https://www.sec.gov/Archives/edgar/data/1652935/000168316826002257/) | [-$21.8 million](https://www.sec.gov/Archives/edgar/data/1652935/000168316826002257/) |
| Cash and equivalents | [$13.2 million](https://www.sec.gov/Archives/edgar/data/1652935/000168316826002257/) | [$8.6 million](https://www.sec.gov/Archives/edgar/data/1652935/000168316825001581/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $4.4 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Actuate Therapeutics

Has Actuate Therapeutics issued a going-concern warning?

Our latest story on this, dated Jun 2, 2025: "Actuate Therapeutics presentation repeats going-concern doubt and need for capital". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/actuate-therapeutics-presentation-repeats-going-concern-doubt-need/).

Has Actuate Therapeutics raised money recently?

Our latest story on this, dated Oct 28, 2026: "Actuate Therapeutics prices $11.0 million offering of shares and warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/actuate-therapeutics-prices-11-0-million-offering-shares-warrants/).

What is the ticker symbol of Actuate Therapeutics?

Actuate Therapeutics, Inc. trades under the ticker ACTU on NASDAQ.

Where is Actuate Therapeutics listed?

Actuate Therapeutics, Inc. is listed on NASDAQ.

What is the SEC CIK of Actuate Therapeutics?

The SEC Central Index Key (CIK) for Actuate Therapeutics, Inc. is 1652935. Its filings are on SEC EDGAR.

How many shares does Actuate Therapeutics have outstanding?

24,014,202 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14.

Which country or territory is Actuate Therapeutics listed under?

Our directory records Actuate Therapeutics, Inc. under United States.

What does Actuate Therapeutics do?

Our directory classifies Actuate Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Actuate Therapeutics?

The ISIN recorded for Actuate Therapeutics, Inc. is US0050831009.

Does aibio.space cover Actuate Therapeutics?

aibio.space lists Actuate Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Actuate Therapeutics incorporated?

SEC records list its state or country of incorporation as DE.

What does Actuate Therapeutics develop?

Actuate Therapeutics is a clinical-stage biopharmaceutical company developing therapies for high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). Its lead asset is elraglusib, an ATP-competitive small molecule that the company says blocks GSK-3β, a master regulator of signaling pathways that lead to tumor cell survival, growth, migration and invasion.

What is Elraglusib Injection (mPDAC) from Actuate Therapeutics?

Elraglusib Injection (mPDAC): GSK-3β inhibitor given with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer Stage: Phase 2 trial met primary endpoint.

What is Elraglusib Injection (pediatric) from Actuate Therapeutics?

Elraglusib Injection (pediatric): Intravenous GSK-3β inhibitor for recurrent or refractory pediatric solid cancers Stage: Phase 1/2 (Actuate-1902).

Is Actuate Therapeutics profitable?

Actuate Therapeutics, Inc. reported a net loss of $22.2 million for the fiscal year ended Dec 31, 2025, and used $19.2 million of cash in operations, per its annual report to the SEC.

## Investor discussion: Actuate Therapeutics

Members talk about Actuate Therapeutics (ACTU). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Actuate Therapeutics, newest first. Each line links the filing it comes from.

1. 2026-10-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1652935/000168316826008193/actuate_8k.htm)
2. 2026-10-28 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1652935/000168316826008122/actuate_424b5.htm)
3. 2026-10-06 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1652935/000168316826007661/actuate_s1.htm)
4. 2026-07-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1652935/000168316826005616/actuate_8k.htm)
5. 2025-11-28 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1652935/000168316825008730/actuate_424b5.htm)
6. 2025-09-09 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1652935/000168316825006782/actuate_424b5.htm)
7. 2025-06-02 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1652935/000168316825004117/actuate_ex9901.htm)
8. 2025-03-28 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1652935/000168316825001945/actuate_8k.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ACTU on TradingView](https://www.tradingview.com/symbols/NASDAQ-ACTU/).

## SEC filings and registration

- **SEC name**: Actuate Therapeutics, Inc.

- **CIK**: 1652935

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: ACTU (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

- **Business address**: 1751 RIVER RUN, FORT WORTH, TX, 76107

- **Phone**: 847-986-4190

- **Shares outstanding**: 24,014,202 as of 2026-08-13 (10-Q filed 2026-08-14)

### Recent filings (8-K and 6-K are the company's own announcements)

- [S-1](https://www.sec.gov/Archives/edgar/data/1652935/000168316826007661/actuate_s1.htm) filed 2026-10-06
- [10-Q](https://www.sec.gov/Archives/edgar/data/1652935/000168316826006472/actuate_i10q-063026.htm) filed 2026-08-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1652935/000168316826005616/actuate_8k.htm) filed 2026-07-17
- [8-K](https://www.sec.gov/Archives/edgar/data/1652935/000168316826004268/actuate_8k.htm) filed 2026-05-22
- [10-Q](https://www.sec.gov/Archives/edgar/data/1652935/000168316826003909/actuate_i10q-033126.htm) filed 2026-05-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1652935/000168316826003684/actuate_8k.htm) filed 2026-05-11
- [8-K](https://www.sec.gov/Archives/edgar/data/1652935/000168316826003515/actuate_8k.htm) filed 2026-05-06
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/1652935/000168316826002691/actuate_def14a1.htm) filed 2026-04-06

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001652935), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Actuate Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ACTU, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Actuate Therapeutics, Inc.

- **Ticker**: ACTU

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US0050831009

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ACTU/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/actuate-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Actuate Therapeutics (ACTU) news: going concern and offering", 2026-10-31, https://aibio.space/companies/actuate-therapeutics/